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Abstract
Background—Compositional changes within the normal intestinal microbiota have been
associated with the development of various intestinal inflammatory disorders such as pouchitis
and inflammatory bowel diseases (IBD). Therefore, it has been speculated that manipulation of a
dysbiotic intestinal microbiota has the potential to restore microbial homeostasis and attenuate
inflammation.
Methods—We performed community composition analyses by terminal restriction fragment
length polymorphism (T-RFLP) of the bacterial 16S ribosomal RNA gene to investigate the
impact of the probiotic VSL#3 on colonic microbial community composition and development of
TNBS-induced colitis in rats.
Results—TNBS-induced chronic colitis was significantly reduced in VSL#3 fed rats compared
to controls (p < 0.05). T-RFLP analysis revealed distinct microbial communities at luminal versus
mucosal sites. Within the luminal microbiota, chronic colitis was associated with an overall
decrease in bacterial richness and diversity (Margalef's richness, p < 0.01; Shannon diversity, p
<0.01). This decrease in luminal microbial diversity was enhanced in TNBS-treated rats fed
VSL#3 (Margalef's richness, p < 0.001; Shannon diversity, p < 0.001) and significantly correlated
with reduced clinical colitis scores (Pearson correlation p < 0.05).
Conclusions—Our data demonstrate that the probiotic VSL#3 alters the composition of the
intestinal microbiota, and these changes correlate with VSL#3-induced disease protection.
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The human intestinal tract may host as many as 36,000 bacterial species amounting to
approximately 100 trillion microorganisms, collectively referred to as the intestinal
microbiota (1-3). This complex microbial community has co-evolved with its eukaryotic
host and has maintained its privileged niche by contributing a wide array of essential
functions. In fact, the microbiota and its collective prokaryotic-genome contribute to key
physiological processes such as development of the mucosal immune system, metabolism of
polysaccharides, intestinal epithelial cell proliferation/differentiation, intestinal development
and barrier function (4-7).
While it is clear that our symbiotic relationship with bacteria is integral to the normal
function of the human gut, this relationship becomes unbalanced under certain
circumstances resulting in disease. For example, Crohn's disease and ulcerative colitis,
collectively termed inflammatory bowel diseases (IBD), appear to result from a combined
loss of intestinal barrier function and overzealous immune response to the intestinal
microbiota (8,9). Current treatment regimens for IBD include administration of
immunosuppressants such as prednisone, 6-mercaptopurine (6-MP) and azathioprine
(Imuran) (Prometheus Therapeutics and Diagnostics; San Diego, CA) or biologics such as
infliximab (Remicade) (Centocor Ortho Biotech; Horsham, PA) or adalimumab (Humira)
(Abbott Laboratories; Abbott Park, IL) that block activity of the inflammatory cytokine
TNFα. While these therapies have shown efficacy in treating the symptoms of IBD, they
often confer serious side effects and further do not address the underlying basis of the
disease, namely microbial dysbiosis.
The commercially available probiotic VSL#3 (VSL Pharmaceuticals, Fort Lauderdale FL) is
a mixture of 8 strains of lactic acid-producing bacteria (Lactobacillus plantarum,
Lactobacillus delbrueckii subsp. Bulgaricus, Lactobacillus casei, Lactobacillus acidophilus,
Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis and Streptococcus
salivarius subsp. thermophilus). VSL#3 has been shown not only to prevent, but also to
ameliorate established colitis in the Il10-/- murine model (10,11) and to prevent development
of ileitis in the SAMP1/YitFc mice (12). While the mechanism underlying the therapeutic
effect of VSL#3 is currently unknown, it has been speculated that the beneficial activities of
probiotics are propagated through a wide range of effects including inhibition of bacterial
translocation, release of bacteriocidin and lactic acid, production of butyric acid, anti-
oxidative effects, enhancement of epithelial barrier function and the modulation of immune
cell responses (2,10,12-22). These disparate effects may be achieved via the action of by-
products generated by these living organisms or indirectly by altering the population
dynamics of the gut microbiota, thereby resulting in changes to the microbial metabolic
spectrum. The impact of VSL#3 on microbial composition is currently unknown.
In this study we used community fingerprinting of the bacterial 16S rRNA gene to assess
colonic microbial community composition in colitic rats. The presence of chronic colitis
coincided with an overall decrease in bacterial species richness and diversity within the
colonic lumen. In addition, we observed distinct microbial community signatures between
the luminal and mucosally-adherent compartment. Interestingly, we observed that
administration of the probiotic VSL#3 alters species richness and diversity of the luminal,
but not the mucosally-adherent microbial community. Furthermore, decreased richness and
biodiversity of the luminal community correlated with reduced colitis severity in VSL#3-
treated rats. Together our data suggest that the beneficial effects of VSL#3 are mediated, at
least in part, through restructuring of the colonic microbiota.
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Rats and TNBS administration
Male Sprague-Dawley rats (∼ 6 weeks of age) were obtained from Southern Veterinary
Service, PSM, Puerto Rico, USA). Animals were maintained in temperature-controlled
rooms and a 12 hour light-dark cycle. Animals were housed one per cage and received
standard laboratory chow ad libitum. Chronic colitis was induced by prolonged reactivation
as previously described (Appleyard and Wallace, 1995). A volume of 0.5 ml
Trinitrobenzene sulfonic acid (TNBS) at a concentration of 60 mg/ml in 50% ethanol was
administered intracolonically by catheter inserted approximately 8 cm proximal to the anus
under ether anesthesia. Six weeks after the initial TNBS instillation, reactivation was
performed by intravenous tail vein injection of TNBS (5mg/kg body weight in 0.9% saline)
once a day for 3 days. Animals continued to receive TNBS intravenously twice a week for
10 weeks as previously described (23). Animals were sacrificed by intraperitoneal
administration of sodium phenobarbital (65 mg/ml). All procedures involving animals were
approved by the Animal Care and Use Committee at Ponce School of Medicine.
VSL#3 administration
VSL#3 was administered to the VSL#3-fed group (n = 16) in the drinking water while the
non-VSL#3 group (n = 17) received only water beginning one week prior to the initial
induction of colitis until the time of sacrifice (total = 18 weeks). VSL#3 dose (CFU/ml
water) was determined by measuring the number of colony forming units consumed daily by
the animals and adjusted to ensure consumption of at least 5 billion CFU of bacteria per 100
g bodyweight. These calculations were based on a daily intake of 3,600 billion bacteria for
an adult human with a mean weight of 70 kg.
Necropsy and colonic damage
At the time of sacrifice, the colon was dissected and fecal pellets were collected and snap
frozen in liquid nitrogen. The colon was splayed longitudinally, cut in half in the same plane
and scored for macroscopic damage based on a well-defined scoring system (23). The
scoring system consisted of four criteria including: presence of adhesions (0, 1, or 2 for
none, minor and major respectively), diarrhea (0, or 1 for absent or present respectively),
colon thickness (mm), and ulceration (0 for no damage, with increasing scores depending on
the extent of ulceration). Approximately 100 mg of proximal tissue was collected and snap
frozen in liquid nitrogen for T-RFLP analysis.
DNA extraction, T-RFLP and community composition analysis
DNA was extracted from between 50-200 mg of fecal material or 100 mg proximal colon
tissue. Samples were resuspended in lysis buffer containing 20 mg/ml lysozyme and
incubated for 30 minutes at 37°C. Further lysis was performed by adding 10% SDS and
proteinase K to 350 μg/ml. Samples were homogenized using a bead beater and 0.1mm
zirconium beads (BioSpec Products) then processed using a DNA extraction kit (DNeasy;
Qiagen). The bacterial 16S ribosomal RNA gene was amplified by PCR from each sample
using fluorescently labeled primers (forward primer 8F FAM
5′AGAGTTTGATCCTGGCTCAG 3′ and reverse primer 1492R Hex 5′
GGTTACCTTGTTACGACTT 3′). Products were purified using a Qiagen PCR purification
kit then digested with HhaI to generate terminal restriction fragments (T-RFs) of varying
size. The T-RFs were processed by capillary electrophoresis on the ABI 3100 genetic
analyzer. Genemapper software (Applied Biosystems) was used to determine the size, area,
and height of each T-RF. The size of these T-RFs corresponds to different bacteria or
bacterial groups with because of polymorphisms in the 16S RNA gene. Size and abundance
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data from Genemapper were compiled into a data matrix using Sequentix software
(Sequentix, Germany). These data were normalized (individual T-RF peak height as a
proportion of total T-RF peak heights within that sample), transformed by square root, and
compiled into a Bray Curtis similarity matrix using PRIMER v6 (Primer-e Ltd). The T-RF
data was subjected to hierarchical cluster followed by Analysis of Similarity (ANOSIM) to
test for differences in global community composition. Biodiversity of each sample was
measured by Margalef's test for richness and Shannon-Weiner diversity index; differences in
richness or diversity between treatment groups were assessed by t test. The contribution of
specific T-RFs to differences in bacterial composition between groups was assessed by
similarity percentages (SIMPER). SIMPER results were used to generate pie charts of
percent contribution of T-RFs within each group, after a 10% cutoff for low contributors.
Quantitative Real-Time PCR (qPCR) analysis
To assay the number of S. thermophilus in stool and mucosal tissue samples, qPCR was
performed on total DNA extracted from fecal and intestinal tissue samples using the forward
primer, 5′ TTATTTGAAAGGGGCAATTGCT 3′ and reverse primer, 5′
GTGAACTTTCCACTCTCACAC 3′ (24). Fold changes in the concentration of S.
thermophilus in intestinal samples were calculated using the ΔΔCt method.
Statistical analysis
Values are presented as mean ± SEM where “n” represents one tissue from one animal used
for a single replicate of an experiment. Pairwise comparisons were evaluated for statistically
significant differences using two-tailed Student's t test, α = 0.05. Pearson correlation, α =
0.05, was used to assess linear relationships between clinical score and species richness, or
clinical score and species diversity. Statistical analyses were performed using Graph Pad
Instat V3.0 (Graph Pad Software, San Diego CA), and Graph Pad Prism V3.0 (Graph Pad
Software, San Diego CA).
Results
TNBS-induced colitis is significantly reduced by consumption of VSL#3
VSL#3 and other probiotics can elicit beneficial effects in various experimental models of
intestinal inflammation and in pouchitis and IBD (25), although the mechanism by which
these protective effects are achieved remains to be elucidated. To investigate the effect of
the probiotic mixture VSL#3 on experimental colitis in rats, we orally administered VSL#3
to wild type rats beginning 1 week prior to and throughout 18 weeks of treatment with the
colitogenic agent trinitrobenzene sulfonic acid (TNBS). We confirmed that VSL#3 was
successfully administered using quantitative real-time PCR to measure levels of S.
thermophilus, the concentration of which is highest among the components of VSL#3 and
maintained at high levels in the intestine after consumption (12). We found a 64- and 36-
fold increase in S. thermophilus in the feces and colonic mucosa of VSL#3 fed rats
compared to water controls, indicating successful administration of VSL#3. We next
evaluated colitis in these animals and as expected, TNBS induced robust colitis, indicated by
significantly higher clinical scores than non-TNBS-treated rats (p < 0.001) (Figure 1).
Importantly, administration of VSL#3 significantly reduced chronic colitis in TNBS-treated
rats (p < 0.05), suggesting a beneficial effect of this probiotic on colonic inflammation.
VSL#3 consumption decreases the biodiversity of the luminal microbiota
Although the consumption of VSL#3 has been associated with various health benefits such
as amelioration of intestinal inflammation (12,25) (Figure 1), its impact on the endogenous
intestinal microbiota has not been explored. To address this important question, we assessed
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microbial community composition in the stool and colonic tissue of TNBS-treated rats using
terminal restriction fragment length polymorphism (T-RFLP) analysis. We amplified the
bacterial 16S rRNA gene from fecal DNA samples and digested with a restriction
endonuclease to generate terminal restriction fragments (T-RFs). Based upon the abundance
of individual T-RFs within each sample, we assessed species richness (Margalef's richness)
and biodiversity (Shannon diversity) then compared mean values between groups – No
TNBS, TNBS +water, TNBS +VSL#3 (Figure 2A). Interestingly, colitic rats displayed a
significant decrease in luminal microbial diversity (p < 0.01) and richness (p < 0.01)
compared to healthy control rats. Administration of VSL#3 to TNBS-treated rats further
reduced microbial diversity and richness of the luminal microbiota (Margalef's richness and
Shannon diversity: No TNBS vs. TNBS +VSL#3, p < 0.001; TNBS +water vs. TNBS
+VSL#3, p < 0.05) (Figure 2A). We computed the percent contribution of T-RFs within
each treatment group and found that the abundance of individual T-RFs differed between
groups (Figure 2B and Table 1). These findings indicate that administration of VSL#3 alters
the richness and diversity of the luminal microbial community during chronic colitis.
VSL#3 does not alter the biodiversity or species distribution of the mucosally-adherent
microbiota
We next sought to determine if VSL#3 also induces a shift in microbial composition of the
mucosally-adherent microbiota. Using proximal colon tissue DNA of TNBS-treated rats
administered either VSL#3 or water, we utilized T-RFLP to analyze the mucosally-adherent
microbial community. In contrast to its effects on the luminal microbiota, VSL#3
consumption did not affect species richness (p > 0.05) or biodiversity (p > 0.05) (Figure
3A), nor did it affect bacterial distribution in the mucosally-adherent microbiota (Figure 3B
and Table 2). These findings suggest that VSL#3 affects only the composition of the luminal
microbiota.
The luminal and mucosally-adherent microbiota display distinct microbial community
signatures
Microbial communities have been shown to differ in composition across different
anatomical sites in humans (26,27). Accordingly, we employed community fingerprinting by
T-RFLP to evaluate the microbiota of TNBS-treated rats within two distinct sites of the
colon: the luminal contents, and the surface mucosa of the proximal colon. Evaluation of
microbial community composition revealed striking differences between sites. Hierarchical
cluster analysis indicated that microbial communities in the lumen cluster independently
from those inhabiting the surface of the colonic mucosa (Figure 4A). Analysis of Similarity
(ANOSIM) testing confirmed that community composition differed significantly between
luminal and mucosal sites (p < 0.001). Interestingly, the extent of microbial richness and
biodiversity did not differ between luminal and mucosal compartments (Figure 4B).
However, a comparison of T-RFs representing different populations within the bacterial
community showed that only 4 out of the 30 T-RFs identified were shared among the top
90% contributing T-RFs in the luminal and mucosally-adherent microbiota (Table 3 and
Figure 4C). These observations indicate that although microbial richness and diversity do
not differ between luminal and mucosal sites of the colon, these sites harbor highly distinct
microbial communities.
Colitis severity correlates with luminal species richness and diversity in VSL#3-treated
animals
We had observed that VSL#3 decreased the severity of colitis in TNBS-treated rats (Figure
1), and reduced species richness and diversity of the luminal microbiota (Figure 2). We
therefore predicted that colitis severity would correlate with VSL#3-induced changes in
luminal microbial diversity. Accordingly, we assessed the correlation between clinical
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scores and luminal species richness or diversity by Pearson correlation analysis. We found
no correlation between clinical score and species richness, or clinical score and species
diversity in TNBS-treated rats that were not fed VSL#3. However, we found that the clinical
scores of rats fed VSL#3 during TNBS treatment correlated with both species richness and
species diversity (Figure 5). Together, these findings demonstrate that VSL#3-mediated
anti-inflammatory effects correlate with changes in both richness and diversity of the
luminal microbiota.
Discussion
There is a growing body of evidence suggesting that probiotic consumption promotes
gastrointestinal health, representing a new avenue for the treatment of diseases such as
pouchitis and IBD (28,29). Understanding how these healthful effects are conferred will
allow for more rational design of probiotic mixtures and aid in the identification and
development of bacterial strains with greater efficacy. In this study we show that distinct
microbial community signatures exist between the luminal and mucosally-adherent
microbiota of colitic rats. Long-term VSL#3 consumption decreases the biodiversity of the
luminal microbiota, whereas bacterial populations associated with the colonic mucosa
remained relatively unchanged. These findings demonstrate that habitual consumption of a
probiotic mixture is capable of reshaping specific compartments of the intestinal microbiota.
Although it is not clear how probiotics confer their beneficial effects on the intestine, it has
been speculated that consumption of adequate quantities of certain bacteria may result in the
competitive exclusion of disease promoting bacterial strains (30). Here, we demonstrate
using T-RFLP and community composition analyses that TNBS-induced chronic colitis in
rats results in a significant decrease in biodiversity within the colonic microbiota. This
finding is consistent with recent work by Dore and coworkers who used a metagenomic
approach to demonstrate that the diversity of the fecal microbiota in Crohn's patients is
markedly reduced compared to that in healthy controls (31). The loss of key microbial
constituents in the intestine may result in dysfunction of homeostatic processes including
nutrient absorption, metabolism and epithelial barrier function (7). Interestingly, we found
that VSL#3 consumption further enhanced the TNBS-induced decrease in luminal microbial
biodiversity. While these findings may appear counterintuitive, it is plausible that VSL#3
promotes its effects through competitive exclusion of specific deleterious microorganisms. If
this were the case, one would posit that the presence of inflammation would either suppress
the growth of beneficial bacteria or promote the growth of those that are deleterious. A
subsequent influx of VSL#3 may then cause a shift back from this dysbiotic community in
favor of health-promoting species, thus attenuating inflammation but resulting in an overall
decrease in biodiversity. While this decrease in biodiversity was apparent within the luminal
microbiota, it was not observed in the mucosally adherent community of the proximal colon.
Yet it is likely that microbial differences are present at other colonic locations such as
cecum, mid-, and distal colon. Investigating microbial composition at multiple sites will help
establish site specific effects of VSL#3.
At this stage of our investigation, it is unclear how VSL#3-induced changes in microbial
composition affect the status of intestinal inflammation. It is possible that VSL#3 promotes
the presence of protective microorganisms; likely constituents of the probiotic itself that
directly influence host innate responses. It has been reported that VSL#3 modulates barrier
function, intestinal permeability and innate host functions, which if altered, could have a
profound impact on the state of colitis. VSL#3 has been shown to enhance barrier function
through decreased epithelial permeability in Il10-/- mice, correlating with a reduction in
intestinal inflammation (10). Another recent study demonstrated that VSL#3 prevents the
development of ileitis in SAMP1/YitFc mice by enhancing epithelial barrier function and
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activating innate signaling leading to NF-kB activition (12). These effects appear to be
mediated by VSL#3 secreted products (12). This is consistent with reports showing that
probiotic-derived factors are capable of modulating host responses and experimental colitis
(32-35). Additionally, structural components present in probiotic bacteria could profoundly
impact immune response and favor the production of immunosuppressive molecules such as
IL-10 (36).
Overall, our results clarify the impact of probiotic consumption on microbial composition in
the colon. Although the community fingerprinting method used in this study did not allow us
to identify specific bacteria suppressed by VSL#3 consumption, it provides a global
perspective of the changes in architecture of the intestinal microbiota. Undoubtedly, future
studies employing next-generation sequencing will offer the resolution needed to identify
individual constituents in this vast microbial community and provide a clearer picture of the
role of the microbiota in the context of healthy and diseased individuals. Through
metagenomic analyses, it may be possible to pinpoint metabolic pathways altered in disease
states and those modulated by probiotic consumption. When combined, these studies will
yield essential information about the mechanism of action of probiotics in promoting
healthful effects in the intestine.
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Glossary
IBD inflammatory bowel disease
T-RFLP terminal restriction fragment length polymorphism
TNBS Trinitrobenzene sulfonic acid
T-RF terminal restriction fragment
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VSL#3 reduces the severity of chronic colitis in TNBS-treated rats. Proximal colon clinical
scores for non-TNBS-treated rats and TNBS-treated rats that received either VSL#3 or
water. Non-TNBS, n=3; TNBS +water, n = 17, TNBS +VSL#3, n = 16. *p = 0.05. Non-
TNBS vs. TNBS +water, or vs. TNBS +VSL#3, p < 0.001.
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VSL#3 administration decreases the biodiversity of the luminal microbiota. A. Measures of
microbial biodiversity in the luminal compartment of each treatment group. Red = Non-
TNBS (n=7); Blue = TNBS +water (n=6); Green = TNBS +VSL#3 (n=7). *p < 0.05; **p <
0.01; ***p < 0.001. B. Percent contribution of T-RFs within the luminal compartment of
each group (from top 90%). Each color represents a different sized T-RF, indicating a
different bacterial group. Dark grey comprises all species contributing between 1% and 2%,
and light gray comprises species contributing below 1% within each group. Unless shared
among groups, T-RFs contributing < 2% are colored in grey.
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VSL#3 does not affect the biodiversity or species distribution of the mucosally-adherent
microbiota. A. Measures of microbial biodiversity within the mucosally-adherent
compartment of each treatment group (TNBS +water n=17, TNBS +VSL#3 n=16). “ns”
denotes no significant difference between groups. B. Percent contribution of T-RFs within
the luminal compartment of each group (from top 90%). Each color represents a different
sized T-RF indicating a different bacterial group.
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Distinct microbial community communities reside in the colonic lumen and mucosal tissue.
A. Hierarchical cluster analysis of T-RF data from TNBS-treated rats. Mucosally-adherent
populations are represented by blue triangles and luminal populations by green triangles. B.
Measures of microbial biodiversity in the colonic lumen and mucosal tissue. Blue = luminal
(n=13); Green = mucosal (n=33). “ns” denotes no significant difference between groups. C.
Percent contribution of T-RFs from each site (from top 90%). Each color represents a
different sized T-RF indicating a different bacterial group. Regions in bold represent the 4
bacterial groups within the top 90% contributors in the microbiota of both the colonic lumen
and mucosa.
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Clinical score of VSL#3-fed rats correlates with luminal species richness and biodiversity.
Luminal microbial Margalef's richness vs. clinical score (top panel); Pearson correlation for
TNBS/water group, p=0.348; for TNBS/VSL#3, *p=0.021. Luminal microbial Shannon
diversity vs. clinical score (bottom panel); Pearson correlation for TNBS/water group,
p=0.183; for TNBS/VSL#3, p=0.021.
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Table 1
Luminal T-RF abundance
No TNBS TNBS + water TNBS + VSL#3
T-RF
399 14.48 ± 1.519 0.86 ± 0.831*** 0.33 ± 0.331***
205 19.04 ± 1.446 0.17 ± 0.170*** 1.08 ± 0.707***
355 2.13 ± 0.238 NP*** NP***
95 0.75 ± 0.124 NP*** NP***
191 0.27 ± 0.032 NP*** NP***
207 0.22 ± 0.123 23.06 ± 2.534*** 22.38 ± 6.084*
75 1.29 ± 0.238 0.34 ± 0.276* 0.25 ± 0.116**
346 0.64 ± 0.127 NP** NP**
407 0.26 ± 0.062 0.17 ± 0.174 NP**
411 0.20 ± 0.042 NP** NP**
213 0.20 ± 0.051 NP** NP**
97 0.16 ± 0.045 NP** NP**
199 0.15 ± 0.031 NP** NP**
397 2.77 ± 0.968 NP* NP*
390 1.78 ± 0.734 NP* NP*
404 5.11 ± 1.561 0.50 ± 0.449* 4.02 ± 2.941
405 0.60 ± 0.206 4.04 ± 1.169* 3.89 ± 1.385
362 0.11 ± 0.067 0.64 ± 0.207* 0.24 ± 0.157
46 NP 1.40 ± 0.461* 1.56 ± 1.265
226 16.02 ± 2.564 15.11 ± 3.061 16.98 ± 4.689
401 8.65 ± 1.722 8.94 ± 2.412 11.09 ± 2.881
115 4.28 ± 1.520 3.55 ± 1.175 3.86 ± 1.267
81 4.07 ± 0.653 3.44 ± 1.632 2.84 ± 1.502
377 1.91 ± 0.967 3.23 ± 0.690 2.38 ± 0.666
57 1.73 ± 0.708 NP 0.11 ± 0.073
248 1.69 ± 0.699 NP NP
58 1.21 ± 0.410 0.33 ± 0.204 0.32 ± 0.182
62 1.17 ± 0.318 5.22 ± 2.067 2.80 ± 1.592
48 1.00 ± 0.362 NP NP
186 0.98 ± 0.350 4.10 ± 1.599 1.25 ± 0.540
402 0.35 ± 0.200 3.14 ± 1.277 3.43 ± 1.543
30 0.38 ± 0.145 0.34 ± 0.102 0.21 ± 0.172
369 0.29 ± 0.310 NP NP
192 NP 5.21 ± 2.690 1.00 ± 0.946
Mean +/- SEM of normalized T-RF peak heights from top 90% of contributors within either group
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“NP” denotes T-RFs not present within a that group
*Astericks denote significant differences between “No TNBS” and either “TNBS +water” or “TNBS +VSL#3”






p < 0.001 by t test
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Table 2
Mucosal T-RF abundance
TNBS + water TNBS + VSL#3
T-RF
30 10.62 ± 1.955 10.81 ± 2.425
92 8.70 ± 4.135 8.15 ± 4.345
29 7.34 ± 1.302 7.82 ± 1.561
23 7.06 ± 1.422 7.85 ± 1.514
250 6.27 ± 2.668 5.33 ± 2.080
46 5.78 ± 1.460 5.69 ± 1.696
33 5.36 ± 3.505 2.78 ± 1.810
226 4.89 ± 1.315 2.97 ± 1.029
24 4.68 ± 0.764 4.76 ± 1.030
189 4.57 ± 1.387 3.65 ± 1.959
27 4.53 ± 0.803 4.68 ± 0.942
26 3.52 ± 0.635 3.38 ± 0.695
20 2.87 ± 0.731 3.80 ± 1.375
31 2.23 ± 1.051 1.78 ± 0.615
404 2.13 ± 0.883 2.62 ± 0.948
207 1.88 ± 0.714 1.29 ± 0.652
198 1.79 ± 0.727 2.58 ± 0.969
377 1.66 ± 0.496 1.99 ± 0.684
62 1.56 ± 0.472 1.54 ± 0.561
Mean +/- SEM of normalized T-RF peak heights from top 90% of contributors within either group
No significant differences in individual T-RF abundance were found between the groups













Uronis et al. Page 18
Table 3
Luminal and mucosal T-RF abundance
Luminal Mucosal
T-RF
207 22.69 ± 3.349 1.59 ± 0.466***
226 16.12 ± 2.792 3.96 ± 0.821*** ◊
401 10.10 ± 1.857 0.20 ± 0.197***
30 0.27 ± 0.101 10.71 ± 1.477***
20 NP 3.32 ± 0.734***
23 NP 7.44 ± 0.992***
26 NP 3.45 ± 0.448***
27 NP 4.60 ± 0.588***
29 NP 7.58 ± 0.966***
405 3.96 ± 0.883 0.47 ± 0.191**
115 3.72 ± 0.837 0.18 ± 0.092**
46 1.49 ± 0.688 5.74 ± 1.063**
24 1.20 ± 0.960 4.72 ± 0.607**
250 0.54 ± 0.267 5.81 ± 1.630**
92 0.19 ± 0.189 8.43 ± 2.859**
198 0.09 ± 0.095 2.17 ± 0.577**
402 3.30 ± 0.978 0.64 ± 0.432*
81 3.12 ± 1.061 NP*
189 1.05 ± 0.549 4.13 ± 1.137*
362 0.43 ± 0.135 0.06 ± 0.044*
33 NP 4.11 ± 1.932*
62 3.92 ± 1.274 1.55 ± 0.348 ◊
192 2.94 ± 1.413 0.04 ± 0.037
377 2.77 ± 0.475 1.82 ± 0.400 ◊
186 2.57 ± 0.858 0.76 ± 0.269
404 2.40 ± 1.620 2.36 ± 0.618 ◊
118 1.67 ± 1.130 0.09 ± 0.052
Mean +/- SEM of normalized T-RF peak heights from top 90% of contributors within either group
◊
Indicates T-RFs shared among the top 90% contributors of both groups
“NP” denotes T-RFs not present within that group
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***
p < 0.001 by t test
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